Cumberland Pharmaceuticals and Clinigen Group Announce Strategic Alliance

Cumberland Pharmaceuticals, a specialty pharmaceutical company focused on hospital acute care and gastroenterology, has agreed to a strategic alliance with Clinigen Group plc a global pharmaceutical and services company. The alliance will combine Cumberland's and Clinigen's respective strengths, expertise and geographical footprints to maximize the commercial potential of future products.

Cumberland will be responsible for the support of Clinigen's future products through marketing, promotion, and distribution in the U.S. Clinigen will be responsible for the marketing, promotion, distribution and sale of Cumberland's pharmaceutical products outside of the USA, enabling Cumberland to use Clinigen's international reach to enter in to new markets outside of the US.

Clinigen is a specialty pharmaceutical and services company focused on delivering the right drug to the right patient at the right time by providing medicines to patients with high unmet needs through clinical trials, licensed and ethically unlicensed supply. As part of Clinigen's continuing strategy to extend its global presence, this collaboration will build on Clinigen's existing North American relationships by providing complementary support from Cumberland in the development, marketing, promotion and distribution of future products in the US.

Peter George, CEO of Clinigen Group plc, said:

"A key strategic initiative this year has been to develop our Group's global distribution footprint. The US is a particular area of focus where we are looking to initiate a long term strategic partnership and Cumberland was a natural fit as a partner. Working together is a logical move for both companies as we will mutually benefit from each other's distribution expertise and capabilities in our respective regions."

AJ Kazimi, Chairman and CEO of Cumberland, added:

"This alliance with Clinigen creates a new growth driver for both companies that builds on our strengths. We look forward to working closely with Clinigen to bring its future products to patients in the US through our established commercial infrastructure. In turn, our products will gain access to new markets in other parts of the world."